β-Hydroxy-N,N-dimethyl-isobutyramid | 61665-47-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: β-Hydroxy-N,N-dimethyl-isobutyramid
• 英文别名: N,N,3-trimethyl-3-hydroxybutyramide；3-Hydroxy-N,N,3-trimethylbutanamide
• CAS: 61665-47-2
• 化学式: C₇H₁₅NO₂
• 分子量: 145.202
• InChiKey: LRXCEDOYEVYBQR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  Pd(NO2)Cl(MeCN)2 、 β-Hydroxy-N,N-dimethyl-isobutyramid 以 四氢呋喃 为溶剂， 以50%的产率得到
  参考文献：
  名称：

  The synthesis and crystal structure of a remarkable binuclear, double Pd–Cl–H–O–Pd bridged palladium alcohol complex. Catalytic oxidations with molecular oxygen mediated by [{[Me₂C(OH)CH₂CONMe₂]Pd(Cl)NO₂}₂]

  摘要：

  N,N-3-三甲基-3-羟基丁酰胺的 Pd(Cl)NO2 复合物在固态下是二聚体，具有两个 PdâClâHâOâPd 氢键桥；但在溶液中，该复合物是单体，在氧化烯烃时具有催化活性。

  DOI：

  10.1039/c39920001169
• 作为产物：
  描述：

  N,N-二甲基乙酰胺 、 丙酮 生成 β-Hydroxy-N,N-dimethyl-isobutyramid
  参考文献：
  名称：

  Isolation and reactions of .alpha.-lithio N,N-dimethylacetamide

  摘要：

  DOI：

  10.1021/jo00430a004

文献信息

• [EN] PROCESS FOR THE PRODUCTION OF SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO]ALKANEAMIDE DERIVATIVES<br/>[FR] PROCÉDÉ DE PRODUCTION DE DÉRIVÉS DE 2-[2-(PHÉNYL) ÉTHYLAMINO]ALCANEAMIDE SUBSTITUÉS
  申请人：NEWRON PHARM SPA

  公开号：WO2020212352A1

  公开（公告）日：2020-10-22

  The present invention refers to a process for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein R is (C3-C10)alkyl, or ω-trifluoro(C3-C10)alkyl; R1 and R2 are, independently, hydrogen, hydroxy, (C1-C8) alkoxy, (C1-C8) alkylthio, halo, trifluoromethyl or 2,2,2-trifluoroethyl; or one of R1 and R2 is in ortho position to the R-O- group and, taken together with the same R-O-, represents a Formula (A) group where Ro is (C2-C9)alkyl; R3 and R4 are, independently, hydrogen, (C1-C4)alkyl; or R4 is hydrogen and R5 is a group selected from -CH2-OH, -CH2-O-(C1-C6)alkyl, -CH(CH3)-OH, -(CH2)2-S-CH3, benzyl and 4-hydroxybenzyl; or R4 and R5, taken together with the adjacent carbon atom, form a (C3-C6)cycloalkyl residue; R5 and R6 are independently hydrogen or (C1-C6)alkyl; or taken together with the adjacent nitrogen atom form a 5-6 membered monocyclic saturated heterocycle, optionally containing one additional heteroatom chosen among -O-, -S- and -NR7- where R7 is hydrogen or (C1-C6) alkyl; and wherein optionally one or more hydrogen atom in the groups R, R1, R2, R3, R4, R5 and R6, preferably in the R group, can be substituted by a deuterium atom.

  本发明涉及一种制备式(I)化合物或其药学上可接受的盐的方法：其中R为(C3-C10)烷基，或ω-三氟(C3-C10)烷基；R1和R2分别为氢、羟基、(C1-C8)烷氧基、(C1-C8)烷基硫醚、卤素、三氟甲基或2,2,2-三氟乙基；或者R1和R2中的一个位于R-O-基的邻位，并与相同的R-O-一起表示一个Ro为(C2-C9)烷基的式(A)基团；R3和R4分别为氢、(C1-C4)烷基；或者R4为氢且R5为从-CH2-OH、-CH2-O-(C1-C6)烷基、-CH(CH3)-OH、-(CH2)2-S-CH3、苄基和4-羟基苄基中选择的基团；或者R4和R5与相邻的碳原子一起形成一个(C3-C6)环烷基残基；R5和R6独立地为氢或(C1-C6)烷基；或者与相邻的氮原子一起形成一个含有一个额外杂原子的5-6元单环饱和杂环，该额外杂原子可选择在-O-、-S-和-NR7-中，其中R7为氢或(C1-C6)烷基；并且在R、R1、R2、R3、R4、R5和R6中的一个或多个氢原子，优选在R基中，可选择用氘原子取代。
• Piperidine compound and process for preparing the same
  申请人：Takahashi Masami

  公开号：US20070112029A1

  公开（公告）日：2007-05-17

  Disclosed are a novel piperidine compound represented by the general formula [I] below which has an excellent tachykinin receptor antagonizing activity and pharmacologically acceptable salts thereof. [I] In the formula, ring A represents an optionally substituted benzene ring; ring B represents an optionally substituted benzene ring; R 1 represents an optionally substituted hydroxyl group, a thiol group having a substituent, a sulfonyl group having a substituent, or a group represented by the following formula [II]: wherein R 11 represents a carbonyl group having a substituent or a sulfonyl group having a substituent and R 12 represents a hydrogen atom or an optionally substituted alkyl group; R 2 represents a hydrogen atom or the like; Z represents an oxygen atom or a group represented by —N(R 3 )— wherein R 3 represents an optionally substituted alkyl group or the like; R 4a represents an optionally substituted alkyl group; and R 4b represents an optionally substituted alkyl group.

  本发明公开了一种新型哌啶化合物，其通式如下[I]，具有优异的催吐肽受体拮抗活性和药理学上可接受的盐。其中，环A代表可选取代的苯环；环B代表可选取代的苯环；R1代表可选取代的羟基，具有取代基的硫醇基，具有取代基的磺酰基或由下式[II]表示的基团：其中，R11代表具有取代基的羰基基团或具有取代基的磺酰基基团，R12代表氢原子或可选取代的烷基基团；R2代表氢原子或类似物；Z代表氧原子或由—N(R3)—表示的基团，其中R3代表可选取代的烷基基团或类似物；R4a代表可选取代的烷基基团；R4b代表可选取代的烷基基团。
• PROCESS FOR THE PRODUCTION OF SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO]ALKANEAMIDE DERIVATIVES
  申请人：Newron Pharmaceuticals S.p.A.

  公开号：EP3725769A1

  公开（公告）日：2020-10-21

  The present invention refers to a process for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein R is (C3-C10)alkyl, or ω-trifluoro(C3-C10)alkyl; R1 and R2 are, independently, hydrogen, hydroxy, (C1-C8)alkoxy, (C1-C8) alkylthio, halo trifluoromethyl or 2,2,2-trifluoroethyl; or one of R1 and R2 is in ortho position to the R-O- group and, taken together with the same R-O-, represents a group where R0 is (C2-C9)alkyl; R3 and R4 are, independently, hydrogen, (C1-C4)alkyl; or R4 is hydrogen and R5 is a group selected from -CH2-OH, -CH2-O-(C1-C6)alkyl, -CH(CH3)-OH, -(CH2)2-S-CH3, benzyl and 4-hydroxybenzyl; or R4 and R5, taken together with the adjacent carbon atom, form a (C3-C6)cycloalkyl residue; R5 and R6 are independently hydrogen or (C1-C6)alkyl; or taken together with the adjacent nitrogen atom form a 5-6 membered monocyclic saturated heterocycle, optionally containing one additional heteroatom chosen among -O-, -S- and -NR7- where R7 is hydrogen or (C1-C6) alkyl; and wherein optionally one or more hydrogen atom in the groups R, R1, R2, R3, R4, R5 and R6, preferably in the R group, can be substituted by a deuterium atom.

  本发明涉及一种制备式（I）化合物或其药学上可接受的盐的工艺： 其中R为(C3-C10)烷基或ω-三氟(C3-C10)烷基； R1 和 R2 独立地为氢、羟基、(C1-C8)烷氧基、(C1-C8)烷硫基、卤代三氟甲基或 2,2,2-三氟乙基；或 R1 和 R2 中的一个位于 R-O- 基团的正交位置，并与相同的 R-O- 结合在一起表示 其中 R0 为 (C2-C9) 烷基； R3 和 R4 独立地为氢、(C1-C4)烷基；或 R4 为氢，R5 为选自-CH2-OH、-CH2-O-(C1-C6)烷基、-CH(CH3)-OH、-(CH2)2-S-CH3、苄基和 4-羟基苄基的基团；或 R4 和 R5 与相邻碳原子一起形成 (C3-C6)cycloalkyl residue； R5和R6独立地为氢或(C1-C6)烷基；或与相邻的氮原子一起形成5-6个成员的单环饱和杂环，可选地含有一个额外的杂原子，该杂原子可从-O-、-S-和-NR7-中选择，其中R7为氢或(C1-C6)烷基； 其中 R、R1、R2、R3、R4、R5 和 R6 基团中的一个或多个氢原子，最好是 R 基团中的氢原子，可以被一个氘原子取代。
• PROCESS FOR THE PRODUCTION OF SUBSTITUTED 2-[2-(PHENYL)ETHYLAMINO]ALKANEAMIDE DERIVATIVES
  申请人：Newron Pharmaceuticals S.p.A.

  公开号：US20220185766A1

  公开（公告）日：2022-06-16

  The present invention refers to a process for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein R is (C 3 -C 10 )alkyl, or ω-trifluoro(C 3 -C 10 )alkyl; R 1 and R 2 are, independently, hydrogen, hydroxy, (C 1 -C 8 ) alkoxy, (C 1 -C 8 ) alkylthio, halo, trifluoromethyl or 2,2,2-trifluoroethyl; or one of R 1 and R 2 is in ortho position to the R—O— group and, taken together with the same R—O—, represents a Formula (A) group where R 0 is (C 2 -C 9 )alkyl; R 3 and R 4 are, independently, hydrogen, (C 1 -C 4 )alkyl; or R 4 is hydrogen and R 5 is a group selected from —CH 2 —OH, —CH 2 —O—(C 1 -C 6 )alkyl, —CH(CH 3 )—OH, —(CH 2 ) 2 —S—CH 3 , benzyl and 4-hydroxybenzyl; or R 4 and R 5 , taken together with the adjacent carbon atom, form a (C 3 -C 6 )cycloalkyl residue; R 5 and R 6 are independently hydrogen or (C 1 -C 6 )alkyl; or taken together with the adjacent nitrogen atom form a 5-6 membered monocyclic saturated heterocycle, optionally containing one additional heteroatom chosen among —O—, —S— and —NR 7 — where R 7 is hydrogen or (C 1 -C 6 ) alkyl; and wherein optionally one or more hydrogen atom in the groups R, R 1 , R 2 , R 3 , R 4 , R 5 and R 6 , preferably in the R group, can be substituted by a deuterium atom.
• US7390905B2
  申请人：——

  公开号：US7390905B2

  公开（公告）日：2008-06-24